Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

NCT05407987 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

82

Enrollment

OTHER

Sponsor class

Conditions

Gynecologic Cancer
Anemia
Iron-deficiency

Interventions

DRUG: Ferric derisomaltose
DRUG: Placebo

Sponsor

AHS Cancer Control Alberta